Tejpal Gupta1, Sarthak Mohanty1, Sadhana Kannan1, Rakesh Jalali1. 1. Department of Radiation Oncology (T.G.); Epidemiology & Clinical Trials Unit-Clinical Research Secretariat, Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, Navi Mumbai, India (T.G., S.K.); Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India (S.M., R.J.).
Abstract
BACKGROUND: To report on sensorineural hearing loss (SNHL) in a cohort of patients treated with hyperfractionated radiation therapy (HFRT) without upfront platinum-based chemotherapy in average-risk medulloblastoma. METHODS: Hearing thresholds were assessed by ear-specific pure-tone audiograms at stimulus frequencies of 0.25, 0.5, 1, 2, 4, and 8 kilohertz. Audiometric assessments were done serially longitudinally at baseline, between 6-12 months after HFRT, and annually thereafter. Pure-tone audiograms were analyzed and graded according to Brock pediatric ototoxicity grading criteria. RESULTS: Five of 20 (25%) children had communicatively and developmentally significant SNHL (Brock grade 2 or worse) even before starting radiotherapy. On follow-up, new-onset Brock grade 2 or worse ototoxicity was documented in 6 previously normal ears. Eleven patients had preserved hearing in both ears on last audiometric follow-up. Compared with baseline testing, post-HFRT audiometry at 2-3 years showed modest decline in hearing threshold across all frequencies. Age at diagnosis and sex did not significantly impact hearing, while higher cochlear doses trended towards worse hearing outcomes. Tumors that extended more towards one side expectedly showed significant worsening in the ipsilateral ear. There was a differential impact of treatment on the right and left ears with the right ear (and not the left ear) showing significantly worse hearing thresholds in the low-to-intermediate speech frequency range over time. CONCLUSION: The use of HFRT for craniospinal irradiation and conformal tumor bed boost without upfront platinum-based chemotherapy in children with average-risk medulloblastoma results in preserved hearing in a large proportion of patients in the audible speech range.
BACKGROUND: To report on sensorineural hearing loss (SNHL) in a cohort of patients treated with hyperfractionated radiation therapy (HFRT) without upfront platinum-based chemotherapy in average-risk medulloblastoma. METHODS: Hearing thresholds were assessed by ear-specific pure-tone audiograms at stimulus frequencies of 0.25, 0.5, 1, 2, 4, and 8 kilohertz. Audiometric assessments were done serially longitudinally at baseline, between 6-12 months after HFRT, and annually thereafter. Pure-tone audiograms were analyzed and graded according to Brock pediatric ototoxicity grading criteria. RESULTS: Five of 20 (25%) children had communicatively and developmentally significant SNHL (Brock grade 2 or worse) even before starting radiotherapy. On follow-up, new-onset Brock grade 2 or worse ototoxicity was documented in 6 previously normal ears. Eleven patients had preserved hearing in both ears on last audiometric follow-up. Compared with baseline testing, post-HFRT audiometry at 2-3 years showed modest decline in hearing threshold across all frequencies. Age at diagnosis and sex did not significantly impact hearing, while higher cochlear doses trended towards worse hearing outcomes. Tumors that extended more towards one side expectedly showed significant worsening in the ipsilateral ear. There was a differential impact of treatment on the right and left ears with the right ear (and not the left ear) showing significantly worse hearing thresholds in the low-to-intermediate speech frequency range over time. CONCLUSION: The use of HFRT for craniospinal irradiation and conformal tumor bed boost without upfront platinum-based chemotherapy in children with average-risk medulloblastoma results in preserved hearing in a large proportion of patients in the audible speech range.
Entities:
Keywords:
audiometry; medulloblastoma; ototoxicity; radiotherapy; sensorineural hearing loss
Authors: Eugene Huang; Bin S Teh; Douglas R Strother; Quillin G Davis; J Kam Chiu; Hsin H Lu; L Steven Carpenter; Wei Yuan Mai; Murali M Chintagumpala; Michael South; Walter H Grant; E Brian Butler; Shiao Y Woo Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-01 Impact factor: 7.038
Authors: R J Packer; J Goldwein; H S Nicholson; L G Vezina; J C Allen; M D Ris; K Muraszko; L B Rorke; W M Wara; B H Cohen; J M Boyett Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Glenn B Williams; Larry E Kun; Jerome W Thompson; Herbert J Gould; Rose Mary S Stocks Journal: Ann Otol Rhinol Laryngol Date: 2005-04 Impact factor: 1.547
Authors: Suzanne L Wolden; Ira J Dunkel; Mark M Souweidane; Laura Happersett; Yasmin Khakoo; Karen Schupak; David Lyden; Steven A Leibel Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Thomas E Merchant; Ciara J Gould; Xiaoping Xiong; Nicole Robbins; Junhong Zhu; David L Pritchard; Raja Khan; Richard L Heideman; Matthew J Krasin; Larry E Kun Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038